Krystal Biotech, Inc. (NASDAQ:KRYS) Insider Suma Krishnan Sells 25,000 Shares

Krystal Biotech, Inc. (NASDAQ:KRYSGet Free Report) insider Suma Krishnan sold 25,000 shares of the firm’s stock in a transaction dated Monday, March 11th. The shares were sold at an average price of $170.96, for a total transaction of $4,274,000.00. Following the completion of the transaction, the insider now directly owns 1,550,882 shares in the company, valued at approximately $265,138,786.72. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink.

Krystal Biotech Stock Performance

KRYS stock traded down $1.45 during mid-day trading on Monday, hitting $170.39. 637,401 shares of the company were exchanged, compared to its average volume of 399,271. The firm has a market cap of $4.82 billion, a P/E ratio of 2,130.14 and a beta of 0.86. The firm’s 50 day simple moving average is $129.39 and its 200 day simple moving average is $119.48. Krystal Biotech, Inc. has a 1-year low of $71.34 and a 1-year high of $189.97.

Krystal Biotech (NASDAQ:KRYSGet Free Report) last posted its quarterly earnings data on Monday, February 26th. The company reported $0.30 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.52) by $0.82. The business had revenue of $42.14 million during the quarter, compared to analyst estimates of $27.43 million. During the same quarter last year, the business earned ($1.25) earnings per share. On average, equities research analysts predict that Krystal Biotech, Inc. will post 1.61 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

Several research analysts have recently issued reports on the stock. Guggenheim raised their target price on shares of Krystal Biotech from $130.00 to $175.00 and gave the company a “buy” rating in a research note on Tuesday, February 27th. Citigroup lifted their price objective on shares of Krystal Biotech from $160.00 to $195.00 and gave the stock a “buy” rating in a research note on Tuesday, February 27th. Cantor Fitzgerald lifted their price objective on shares of Krystal Biotech from $160.00 to $180.00 and gave the stock an “overweight” rating in a research note on Wednesday, December 13th. The Goldman Sachs Group began coverage on shares of Krystal Biotech in a research note on Monday, November 20th. They set a “buy” rating and a $160.00 price objective on the stock. Finally, William Blair reissued an “outperform” rating on shares of Krystal Biotech in a research note on Tuesday, February 27th. Nine equities research analysts have rated the stock with a buy rating, Based on data from MarketBeat, the company currently has an average rating of “Buy” and a consensus price target of $157.67.

Read Our Latest Stock Analysis on Krystal Biotech

Institutional Trading of Krystal Biotech

A number of hedge funds and other institutional investors have recently made changes to their positions in the business. Vanguard Group Inc. raised its holdings in shares of Krystal Biotech by 1.5% in the fourth quarter. Vanguard Group Inc. now owns 2,435,774 shares of the company’s stock valued at $302,182,000 after purchasing an additional 35,632 shares during the last quarter. BlackRock Inc. raised its holdings in shares of Krystal Biotech by 1.0% in the first quarter. BlackRock Inc. now owns 1,716,095 shares of the company’s stock valued at $137,391,000 after purchasing an additional 16,499 shares during the last quarter. State Street Corp raised its holdings in shares of Krystal Biotech by 52.3% in the first quarter. State Street Corp now owns 1,068,656 shares of the company’s stock valued at $71,108,000 after purchasing an additional 366,855 shares during the last quarter. Jennison Associates LLC increased its holdings in Krystal Biotech by 112.5% during the fourth quarter. Jennison Associates LLC now owns 724,344 shares of the company’s stock worth $89,862,000 after buying an additional 383,495 shares during the last quarter. Finally, First Light Asset Management LLC increased its holdings in Krystal Biotech by 5.6% during the first quarter. First Light Asset Management LLC now owns 717,936 shares of the company’s stock worth $47,771,000 after buying an additional 37,766 shares during the last quarter. 82.30% of the stock is currently owned by institutional investors and hedge funds.

About Krystal Biotech

(Get Free Report)

Krystal Biotech, Inc, a biotechnology company, develops and commercializes genetic medicines for patients with rare diseases in the United States. It develops beremagene geperpavec (B-VEC) for dystrophic epidermolysis bullosa; KB105 for treating patients with deficient autosomal recessive congenital ichthyosis; KB104 for netherton syndrome; and KB407 for Cystic Fibrosis.

See Also

Insider Buying and Selling by Quarter for Krystal Biotech (NASDAQ:KRYS)

Receive News & Ratings for Krystal Biotech Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Krystal Biotech and related companies with MarketBeat.com's FREE daily email newsletter.